Personalis Inc PSNL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
-
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
-
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
-
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
-
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
-
Personalis to Participate in Upcoming Investor Events
-
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
-
Personalis Reports First Quarter Results and Recent Highlights
Trading Information
- Previous Close Price
- $15.58
- Day Range
- $15.18–16.39
- 52-Week Range
- $3.84–16.39
- Bid/Ask
- $15.40 / $15.55
- Shares Outstanding
- 104.72M
- Market Cap
- $1.61B
- Volume/Avg
- 7M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.29
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 260
- Website
- https://www.personalis.com
Valuation
|
Metric
|
PSNL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.32 |
Price/Sales | 22.29 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PSNL
|
|---|---|
Quick Ratio | 6.31 |
Current Ratio | 6.61 |
Interest Coverage | −458.03 |
Quick Ratio
PSNL
Profitability
|
Metric
|
PSNL
|
|---|---|
Return on Assets (Normalized) | −30.62% |
Return on Equity (Normalized) | −40.46% |
Return on Invested Capital (Normalized) | −36.15% |
Return on Assets
PSNL
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|>q&X#pG! | LOCK|Z^ | $198B | |||
| Danaher Corp
DHR
| LOCK|N#w<V%K | LOCK|CZ | $144B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|Y@?kDH$ | LOCK|>x | $45B | |||
| Agilent Technologies Inc
A
| LOCK|VbQ&Y!yj | LOCK|d> | $37B | |||
| Waters Corp
WAT
| LOCK|F>GwbfF | LOCK|^M^ | $36B | |||
| IQVIA Holdings Inc
IQV
| LOCK|MXC#<n | LOCK|ycJ< | $34B | |||
| Illumina Inc
ILMN
| LOCK|R$%DQP | LOCK|GH%!< | $28B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|R^g&^^&M | LOCK|cD^% | $26B | |||
| Quest Diagnostics Inc
DGX
| LOCK|rL#qf&M | LOCK|htL# | $23B | |||
| Labcorp Holdings Inc
LH
| LOCK|HY%?#W$ | LOCK|q@$$^ | $23B |
United States